vs
Fortrea Holdings Inc.（FTRE）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Fortrea Holdings Inc.的季度营收约是VERACYTE, INC.的4.7倍（$660.5M vs $140.6M）。VERACYTE, INC.净利率更高（29.3% vs -4.9%，领先34.2%）。VERACYTE, INC.同比增速更快（18.5% vs -5.2%）。Fortrea Holdings Inc.自由现金流更多（$121.6M vs $48.8M）。过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs -0.1%）
Fortrea Holdings Inc.是一家总部位于美国北卡罗来纳州达勒姆、注册地为特拉华州的合同研究组织，业务覆盖90个国家，主要服务制药、生物技术和医疗器械行业客户，为相关领域的研发提供专业支持。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
FTRE vs VCYT — 直观对比
营收规模更大
FTRE
是对方的4.7倍
$140.6M
营收增速更快
VCYT
高出23.8%
-5.2%
净利率更高
VCYT
高出34.2%
-4.9%
自由现金流更多
FTRE
多$72.8M
$48.8M
两年增速更快
VCYT
近两年复合增速
-0.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $660.5M | $140.6M |
| 净利润 | $-32.5M | $41.1M |
| 毛利率 | — | 72.5% |
| 营业利润率 | -2.1% | 26.4% |
| 净利率 | -4.9% | 29.3% |
| 营收同比 | -5.2% | 18.5% |
| 净利润同比 | 46.9% | 704.8% |
| 每股收益（稀释后） | $-0.25 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTREVCYT
| Q4 25 | $660.5M | $140.6M | ||
| Q3 25 | $701.3M | $131.9M | ||
| Q2 25 | $710.3M | $130.2M | ||
| Q1 25 | $651.3M | $114.5M | ||
| Q4 24 | $697.0M | $118.6M | ||
| Q3 24 | $674.9M | $115.9M | ||
| Q2 24 | $662.4M | $114.4M | ||
| Q1 24 | $662.1M | $96.8M |
净利润FTREVCYT
| Q4 25 | $-32.5M | $41.1M | ||
| Q3 25 | $-15.9M | $19.1M | ||
| Q2 25 | $-374.9M | $-980.0K | ||
| Q1 25 | $-562.9M | $7.0M | ||
| Q4 24 | $-61.2M | $5.1M | ||
| Q3 24 | $-27.9M | $15.2M | ||
| Q2 24 | $-138.4M | $5.7M | ||
| Q1 24 | $-101.0M | $-1.9M |
毛利率FTREVCYT
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% | ||
| Q1 24 | — | 64.5% |
营业利润率FTREVCYT
| Q4 25 | -2.1% | 26.4% | ||
| Q3 25 | -1.2% | 17.4% | ||
| Q2 25 | -46.5% | -4.0% | ||
| Q1 25 | -79.9% | 2.5% | ||
| Q4 24 | -8.0% | 3.5% | ||
| Q3 24 | -2.7% | 10.4% | ||
| Q2 24 | -7.7% | 4.0% | ||
| Q1 24 | -5.6% | -4.8% |
净利率FTREVCYT
| Q4 25 | -4.9% | 29.3% | ||
| Q3 25 | -2.3% | 14.5% | ||
| Q2 25 | -52.8% | -0.8% | ||
| Q1 25 | -86.4% | 6.2% | ||
| Q4 24 | -8.8% | 4.3% | ||
| Q3 24 | -4.1% | 13.1% | ||
| Q2 24 | -20.9% | 5.0% | ||
| Q1 24 | -15.3% | -1.9% |
每股收益（稀释后）FTREVCYT
| Q4 25 | $-0.25 | $0.50 | ||
| Q3 25 | $-0.17 | $0.24 | ||
| Q2 25 | $-4.14 | $-0.01 | ||
| Q1 25 | $-6.25 | $0.09 | ||
| Q4 24 | $-0.68 | $0.07 | ||
| Q3 24 | $-0.31 | $0.19 | ||
| Q2 24 | $-1.55 | $0.07 | ||
| Q1 24 | $-1.13 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $174.6M | $362.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $563.5M | $1.3B |
| 总资产 | $2.7B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FTREVCYT
| Q4 25 | $174.6M | $362.6M | ||
| Q3 25 | $131.3M | $315.6M | ||
| Q2 25 | $81.2M | $219.5M | ||
| Q1 25 | $101.6M | $186.1M | ||
| Q4 24 | $118.5M | $239.1M | ||
| Q3 24 | $105.3M | $274.1M | ||
| Q2 24 | $126.2M | $235.9M | ||
| Q1 24 | $92.8M | $209.2M |
股东权益FTREVCYT
| Q4 25 | $563.5M | $1.3B | ||
| Q3 25 | $580.8M | $1.3B | ||
| Q2 25 | $589.2M | $1.2B | ||
| Q1 25 | $858.8M | $1.2B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.6B | $1.1B |
总资产FTREVCYT
| Q4 25 | $2.7B | $1.4B | ||
| Q3 25 | $2.7B | $1.4B | ||
| Q2 25 | $2.8B | $1.3B | ||
| Q1 25 | $3.1B | $1.3B | ||
| Q4 24 | $3.6B | $1.3B | ||
| Q3 24 | $3.7B | $1.3B | ||
| Q2 24 | $3.6B | $1.2B | ||
| Q1 24 | $4.2B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $129.1M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $121.6M | $48.8M |
| 自由现金流率自由现金流/营收 | 18.4% | 34.7% |
| 资本支出强度资本支出/营收 | 1.1% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $88.3M | $126.6M |
8季度趋势，按日历期对齐
经营现金流FTREVCYT
| Q4 25 | $129.1M | $52.6M | ||
| Q3 25 | $86.8M | $44.8M | ||
| Q2 25 | $21.8M | $33.6M | ||
| Q1 25 | $-124.2M | $5.4M | ||
| Q4 24 | $17.1M | $24.5M | ||
| Q3 24 | $-2.4M | $30.0M | ||
| Q2 24 | $273.7M | $29.6M | ||
| Q1 24 | $-25.6M | $-9.0M |
自由现金流FTREVCYT
| Q4 25 | $121.6M | $48.8M | ||
| Q3 25 | $79.5M | $42.0M | ||
| Q2 25 | $14.3M | $32.3M | ||
| Q1 25 | $-127.1M | $3.5M | ||
| Q4 24 | $13.9M | $20.4M | ||
| Q3 24 | $-10.6M | $27.7M | ||
| Q2 24 | $262.5M | $26.8M | ||
| Q1 24 | $-34.9M | $-11.1M |
自由现金流率FTREVCYT
| Q4 25 | 18.4% | 34.7% | ||
| Q3 25 | 11.3% | 31.8% | ||
| Q2 25 | 2.0% | 24.8% | ||
| Q1 25 | -19.5% | 3.1% | ||
| Q4 24 | 2.0% | 17.2% | ||
| Q3 24 | -1.6% | 23.9% | ||
| Q2 24 | 39.6% | 23.4% | ||
| Q1 24 | -5.3% | -11.5% |
资本支出强度FTREVCYT
| Q4 25 | 1.1% | 2.7% | ||
| Q3 25 | 1.0% | 2.1% | ||
| Q2 25 | 1.1% | 1.0% | ||
| Q1 25 | 0.4% | 1.6% | ||
| Q4 24 | 0.5% | 3.5% | ||
| Q3 24 | 1.2% | 1.9% | ||
| Q2 24 | 1.7% | 2.4% | ||
| Q1 24 | 1.4% | 2.2% |
现金转化率FTREVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTRE
暂无分部数据
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
